Justia U.S. Federal Circuit Court of Appeals Opinion Summaries

Valles began working for the State Department as a passport specialist in 2011. In 2016, Valles served a three-day suspension for charges concerning inappropriate sexual and political comments made to co-workers and customers. In 2018, Valles served a five-day suspension for failure to follow instructions and failure to protect personally identifiable information. In 2019, Valles received a performance appraisal of “Fully Successful” for 2018.The agency nonetheless proposed Valles’ removal based on four charges from 18 specifications dating between July 2018 and February 2019. Some of the alleged conduct occurred during the 2018 evaluation period. The charges included failure to follow instructions, failure to properly move along applications and provide updates, leaving a passport application on a photocopier, failure to follow policies concerning the handling of fees, not maintaining control over applications, leaving his adjudication stamp unsecured, and drinking from a wine glass at his workstation in the public counter.An administrative judge upheld the termination. The Federal Circuit affirmed. The agency proved all the charges and established a nexus between the proven misconduct and the agency’s ability to carry out its mission. The penalty was reasonable, considering all the relevant “Douglas” factors, including the repeated nature and seriousness of the misconduct, Valles’ prior discipline, his seven years of federal service and job performance, the consistency of the penalty with similar cases, and the lack of rehabilitation potential on Valles’ part. View "Valles v. Department of State" on Justia Law

A 2005 Customs ruling letter stated that Kent’s imported bicycle seats would be classified as “accessories of bicycles” under HTSUS heading 8714, with a 10% ad valorem duty. In 2008, after Customs classified a competitor’s bicycle seats as “seats” under duty-free heading 9401. Kent started filing protests, post-entry amendments, and an application for further review. Customs approved the protests and reliquidated Kent’s merchandise under heading 9401. Kent sought revocation of the 2005 Ruling but continued to make entries through New York and lodged protests for each. Customs stopped granting those protests. Kent began to import the same merchandise through Long Beach under heading 8714. Long Beach Customs treated these entries as bypass entries and liquidated them under heading 8714 without examination or Customs officer review. Kent protested. Although the New York protests were granted, Kent’s Long Beach protests were denied. In 2014, Customs revoked its earlier decisions classifying Kent’s competitors’ merchandise under heading 9401, concluding that the merchandise would be classified under heading 8714. Customs declined to revoke the 2005 Ruling.The Trade Court rejected Kent’s claims that the classification violated 19 U.S.C. 1625(c) by departing from a “treatment previously accorded” and was contrary to a de facto “established and uniform practice” (EUP) under section 1315(d). The Federal Circuit reversed. The Trade Court erred in approving Customs’ use of bypass entries to show the absence of treatment previously accorded but properly found no de facto EUP. View "Kent International, Inc. v. United States" on Justia Law

Celgene markets pomalidomide as a multiple-myeloma drug under the brand name Pomalyst. Many drug companies questioned the validity or applicability of Celgene's patents and sought to bring generic pomalidomide to market. The defendants submitted an abbreviated new drug application (ANDA) to the FDA. Celgene filed suit in New Jersey. Celgene is headquartered there, but no defendant is. MPI is based in West Virginia, Mylan Inc. in Pennsylvania, and Mylan N.V. in Pennsylvania and the Netherlands. The district court dismissed the case for improper venue (MPI; Mylan Inc.) and for failure to state a claim (as to Mylan N.V.).The Federal Circuit affirmed. Under the Hatch-Waxman Act, 21 U.S.C. 355(j)(5)(B)(iii), venue was improper in New Jersey for the domestic corporation defendants, MPI and Mylan Inc. Celgene did not show that those defendants committed acts of infringement in New Jersey and have a regular and established place of business there. The court rejected Celgene’s argument that receipt of the ANDA notice letter is an infringing act in New Jersey. Under section 271(e)(2), submitting an ANDA is the act of infringement; although the ANDA applicant must later send a notice letter that happens after the infringing submission. As to the foreign-corporation defendant, Mylan N.V., Celgene’s pleadings failed to state a claim upon which relief could be granted. View "Celgene Corp. v. Mylan Pharmaceuticals Inc." on Justia Law

Methicillin-resistant Staphylococcus aureus (MRSA), and other Gram-positive bacteria that have developed resistance to antibiotics cause health problems, particularly in the hospital environment. TheUniversity of Strathclyde’s 706 patent addresses problems resulting from the “availability of few effective sterili[z]ation methods for environmental decontamination” of air and surfaces and discloses photoinactivation as a method that has emerged for killing harmful bacteria like MRSA and describes a method for photo-inactivating antibiotic-resistant bacteria like MRSA without using a photosensitizing agent.In inter partes review, the Patent Trial and Appeal Board found claims 1–4 of the 706 patent unpatentable as obvious, 35 U.S.C. 103. The Federal Circuit reversed. Neither the Board’s finding that the prior art disclosed all claim limitations nor its finding of a reasonable expectation of success is supported by substantial evidence. No reasonable factfinder could have found that the combination of the prior art discloses inactivating one or more Gram-positive bacteria without using a photosensitizer. In this case, where the prior art establishes only failures to achieve that at which the inventors succeeded, no reasonable factfinder could find an expectation of success based on the teachings of that same prior art. View "University of Strathclyde v. Clear-Vu Lighting, LLC" on Justia Law

Courtney, an Equal Employment Opportunity Commission (EEOC) Investigator, was removed from her federal employment effective December 7, 2019, based on a charge of being absent without leave. Her removal was affirmed by the Merit Systems Protection Board and Federal Circuit. Courtney applied to the Office of Personnel Management (OPM) for disability retirement benefits, asserting that she suffered from vision-related ailments, asthma, and diabetes. As a result of the vision problems, she said, she was unable to perform her duties, which were all computer-based, and she had difficulty commuting. Courtney alleged that she had requested reasonable accommodations that were not granted. The EEOC indicated that requested reasonable accommodations had been provided and that Courtney’s performance even with her alleged disability “was not less than fully successful” (even if her conduct was unsatisfactory).OPM denied her application, concluding that Courtney had failed to establish that her medical condition was incompatible with useful service or that the agency-provided reasonable accommodations were ineffective. The Merit Systems Protection Board and Federal Circuit affirmed, agreeing with an administrative judge that although Courtney met some of the requirements for disability retirement, she had not established that she was unable “to render useful and efficient service” in light of her disability—a requirement of 5 U.S.C. 8451(a)(1)(B). View "Courtney v. Office of Personnel Management" on Justia Law

Qualcomm accused Apple of infringing various patents. Apple petitioned the Patent Trial and Appeal Board for inter partes review (IPR) of those patents. In 2019, the parties settled all their patent-infringement litigation worldwide and entered a six-year global patent license agreement with a two-year extension option, resulting in the dismissal of the infringement case with prejudice. The Board determined that Apple failed to prove various claims unpatentable. The Federal Circuit dismissed Apple’s appeal for lack of standing.Subsequently, Qualcomm again accused Apple of infringement and Apple again sought IPR. Then came the settlement and license agreement, resulting in the dismissal of the district court action with prejudice. The Board then issued final written decisions concluding that Apple had not proven various claims unpatentable. The Federal Circuit again dismissed an appeal for lack of Article III standing and rejected Apple’s request that, if it lacked jurisdiction, it should vacate the Board’s decisions “to eliminate any doubt about the applicability of estoppel.” View "Apple Inc. v. Qualcomm Inc." on Justia Law

Courtney, an Equal Employment Opportunity Commission Investigator. was removed from her federal employment effective December 7, 2019, premised on a charge of being absent without leave (AWOL) for several months. An administrative judge first determined that the EEOC had proven its AWOL charge by a preponderance of the evidence then determined that Courtney had failed to establish her affirmative defenses—allegations of retaliation for EEO activity, discrimination based on disability, and harmful procedural errors. The administrative judge determined that there was a nexus between the AWOL charge and the efficiency of the federal service because an “essential element of employment is to be on the job when one is expected to be there” and agreed that removal was appropriate given the agency’s thorough analysis, which relied on the seriousness of Courtney’s misconduct, the length of her absence, and her supervisor’s statement regarding a loss in confidence in her based on her failures to communicate.The Merit Systems Protection Board and the Federal Circuit affirmed, noting evidence that Courtney was AWOL from March 25 to December 7, 2019, that she provided no medical excuse for her absence, and that the EEOC had granted every requested accommodation. View "Courtney v. Equal Employment Opportunity Commission" on Justia Law

Ravgen filed suit in the federal district court in Waco, Texas, accusing Quest’s QNatal Advanced test of infringing patents relating to non-invasive tests for prenatal genetic disorders. Quest moved to transfer the case (28 U.S.C. 1404(a)), arguing that the Central District of California was a more convenient forum; its knowledgeable employees work in that district and third-party witnesses reside in the district. Although Quest maintains patient service centers across the country—including in the Western District of Texas—Quest designed, developed, and continues to perform QNatal Advanced testing only in the Central District of California. Quest argued that Ravgen, headquartered in Maryland, has no meaningful connections to the Western District of Texas. Ravgen noted that it had filed three related complaints in the Western District of Texas, alleging infringement of the same patents. After analyzing the public and private interest factors that govern transfer determinations, the district court denied Quest’s motion.The Federal Circuit directed the district court to transfer the case. When there are numerous witnesses in the transferee venue and the only other witnesses are far outside the plaintiff’s chosen forum, the witness-convenience factor favors transfer. The court erroneously discounted documents located in California that relate to the development, validation, testing, and performance of the accused product and in weighing court congestion as strongly against transfer. View "In Re Quest Diagnostics, Inc." on Justia Law

In 2007, ROHM Japan and MaxPower entered into a technology license agreement (TLA). ROHM Japan was permitted “to use certain power [metal oxide semiconductor field-effect transistors (MOSFET)]-related technologies of” MaxPower (Licensor) developed under a Development and Stock Purchase Agreement in exchange for royalties paid to MaxPower. The TLA, as amended in 2011, includes an agreement to arbitrate “[a]ny dispute, controversy, or claim arising out of or in relation to this Agreement or at law, or the breach, termination, or validity thereof.” Arbitration is to be conducted “in accordance with the provisions of the California Code of Civil Procedure.”In 2019, a dispute arose between ROHM Japan and MaxPower concerning whether the TLA covers ROHM’s silicon carbide MOSFET products. MaxPower notified ROHM Japan of its intent to initiate arbitration. Shortly thereafter, ROHM's subsidiary, ROHM USA, sought a declaratory judgment of noninfringement of four MaxPower patents in the Northern District of California and four inter partes review petitions. The district court granted MaxPower’s motion to compel arbitration and dismissed the case without prejudice, reasoning that the TLA “unmistakably delegate[s] the question of arbitrability to the arbitrator.” The Federal Circuit affirmed. In contracts between sophisticated parties, incorporation of rules with a provision on the subject is normally sufficient “clear and unmistakable” evidence of the parties’ intent to delegate arbitrability to an arbitrator. View "ROHM Semiconductor USA, LLC v. MaxPower Semiconductor, Inc." on Justia Law

In 2007, Galperti-Italy, to support its application to the Patent and Trademark Office (PTO) for registration of the mark GALPERTI, told the PTO that, in the five preceding years, its use of the mark was “substantially exclusive.” In 2008, the PTO granted the application and issued Registration No. 3411812. In 2013, Galperti-USA petitioned the PTO to cancel the registration, 15 U.S.C. 1064, arguing that the registration was obtained by fraud because Galperti-Italy’s 2007 statement of substantially exclusive use was intentionally false. The Trademark Trial and Appeal Board, on remand, dismissed the fraud claim, again finding no proven falsity of the statement at issue (and again not reaching the intent aspect of fraud).The Federal Circuit vacated. in finding no falsity of Galperti-Italy’s assertion of substantially exclusive use in 2002-2007, the Board committed two legal errors: requiring Galperti-USA to establish its own proprietary rights to the mark and disregarding the use of the mark by others during the period at issue. The court noted that Galperti is a surname. Galperti-USA does not need to establish secondary meaning of its own uses of GALPERTI in order for those uses to be counted in determining the falsity of Galperti-Italy’s claim of substantially exclusive use. View "Galperti, Inc. v. Galperti S.R.L." on Justia Law